Rezum™

Water Vapour Therapy

Rezum Overview

Relief that lasts.

Rezūm Water Vapour Therapy is a minimally invasive, first-line alternative that uses thermal energy to remove the excess prostate tissue causing BPH symptoms, providing durable results and lasting relief.1


 

How Rezūm Therapy Works

Rezum

This straightforward therapy enables providers to reduce prostate volume, including obstructive median lobes, while preserving erectile and ejaculatory function, and can be performed in a variety of clinical settings.1,2

During each 9-second treatment, sterile water vapour is released throughout the targeted prostate tissue. When the steam contacts the prostate tissue, the stored energy is released in the tissue. Over time, the body´s healing response reabsorbs the treated tissue, shrinking the prostate.


 

Why choose Rezūm Water Vapour Therapy?

Durable LUTS improvement

Through 5 years, patients treated with Rezūm Therapy saw sustained improvements, in IPSS,IPPS-QOL,BPH II, and Qmax of 48%, 45%, 48% and 44% over baseline, respectively(P<.0001 for all). In a pivotal study, Rezūm Therapy demonstrated a 4.4% surgical retreatment rate and 11.1% medication retreatment  rate at 5 years.1

High patient satisfaction

Rezūm Therapy delivers high patient satisfaction. A 4-year single-centre study of 255 men demonstrated high satisfaction with Rezūm Therapy: 91% had satisfaction with outcomes, 94% of patients were satisfied overall, and 97% of patients would recommend to a friend.3

Straightforward procedure

Rezūm Therapy had an average procedure time of just over 5 minutes in the pivotal trial and has the ability to treat lateral and central zones without physicians having to learn an advanced technique. Rezūm therapy can also be performed in a range of sites of service, including a physician office, ambulatory surgery centre (ASAC), or in a hospital outpatient setting.1

Cost-effective

Rezūm Therapy is cost-effective for both patients and institutions. When comparing the total Medicare patients costs at 5 years, Rezūm Therapy was one third the cost of prostatic urethral lift (PUL) and more effective, generating greater Quality Adjusted Life Years (QAYLs)- Rezūm Therapy was also more effective and less costly than combination drug therapy (CT) over the 5 year time horizon.4

Introducing the RezūmTM EVO Console

The Rezūm EVO Console is designed to enhance the user experience for urologists and their staff, while continuing to support long-term LUTS relief and high patient satisfaction with Rezūm Water Vapour Therapy.1,3,5
The Rezūm EVO Console features a smaller footprint with improved mobility, providing greater ease of use in a variety or range of care settings. With its durable design and intuitive user interface, the Rezūm EVO Console is intended to help staff of all experience levels to work efficiently and independently.

Improved operational efficiency

The Rezūm EVO Console features a 3D-animated, touch-guided user interface with an intuitive design intended to accelerate the operational learning curve and to improve ease of use for staff. Audible and visual cues are designed to minimize disruptions for staff and urologists, providing information on:

  • Replacing the irrigation bag
  • Refilling the sterile water syringe
  • Draining the patient´s bladder

Care setting flexibility

Compared to the previous generation, the Rezūm EVO Console provides enhanced mobility with a smaller footprint, so you can treat patients in a variety of care settings-including those limited by space. 

The mobility pole is engineered to provide enhanced manoeuvrability with a pole handle and low-roll resistance wheels. The height-adjustable pole optimizes console viewing height during setup and treatment.5

Durable by design

The Rezūm EVO Console features an innovative architecture designed for reliable, lasting performance, so you can invest with confidence.

 

Rezūm water vapour therapy vs. other common treatments

Rezūm Therapy Prostatic urethral lift7
Reported treatment effect (through 5 years) 11.1 point mean IPSS improvement1 7.9 point mean IPSS improvement
Surgical retreatment rate (through 5 years) 4.4%1 13.6%7
General anaesthesia required No No
Permanent implant No Yes
Impact on sexual function No clinically meaningful impact to erectile or ejaculatory function.2 No clinically meaningful impact to erectile or ejaculatory function.7
Return to usual activities Median 4 days6 Median 8.6 days7
Removes tissues? Yes No
Recommended by the American Urological Association for use in patients with a median lobe? Yes No
Rezūm Therapy BPH Medications
Reported treatment effect 11.1 point mean IPSS improvement (Through 5 years)1 Mean IPSS improvement from 12 months8:
• 8.8 points (Alpha-blockers)
• 6.8 points (5-ARIs)
• 9.9 points (Combination)
Impact on sexual function No clinically meaningful impact to erectile or ejaculatory function.2 Notable side effects to combination therapy (alpha blockers and 5 ARIs) include:9
• Erectile dysfunction
• Ejaculatory dysfunction
• Decreased sexual desire
• Decreased satisfaction with sex life
Disease progression 0.8% disease progression over a 3-year period8 Approximately 5 times greater disease progression for mono and combination therapy when compared to Rezūm over a 3-year period8
• 4.8% (Alpha-blockers)
• 4.0% (5-ARIs)
• 4.7% (Combination)

 
Rezum

Get in touch with our team

Whether you´re looking to get started with Rezūm Therapy or have general questions about the product, procedure, or clinical data, our team is here to help

Top